Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

2.

Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.

Lu J, Sun T, Wang D, Dong Y, Xu M, Hou H, Kong FT, Liang C, Gu T, Chen P, Sun S, Lv X, Jiang C, Kong W, Wu Y.

Immunol Invest. 2015;44(5):482-96. doi: 10.3109/08820139.2015.1037956.

PMID:
26107747
3.
4.
5.

PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.

Xin W, Li Y, Mo H, Roland KL, Curtiss R 3rd.

Infect Immun. 2009 Oct;77(10):4518-28. doi: 10.1128/IAI.00486-09.

6.

Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.

Briles DE, Hollingshead SK, King J, Swift A, Braun PA, Park MK, Ferguson LM, Nahm MH, Nabors GS.

J Infect Dis. 2000 Dec;182(6):1694-701.

PMID:
11069242
7.
8.

Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice.

Tart RC, McDaniel LS, Ralph BA, Briles DE.

J Infect Dis. 1996 Feb;173(2):380-6.

PMID:
8568299
9.
10.

Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.

Lin H, Peng Y, Lin Z, Zhang S, Guo Y.

Microb Pathog. 2015 Jun-Jul;83-84:35-40. doi: 10.1016/j.micpath.2015.04.006.

PMID:
25959527
11.

Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Langermann S, Palaszynski SR, Burlein JE, Koenig S, Hanson MS, Briles DE, Stover CK.

J Exp Med. 1994 Dec 1;180(6):2277-86.

12.

Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.

Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH.

Vaccine. 2011 Aug 5;29(34):5731-9. doi: 10.1016/j.vaccine.2011.05.095.

PMID:
21696869
13.
14.

Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.

Meng C, Lin H, Huang J, Wang H, Cai Q, Fang L, Guo Y.

Microb Pathog. 2009 Sep;47(3):151-6. doi: 10.1016/j.micpath.2009.05.004.

PMID:
19467319
15.
16.

A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.

Kothari N, Kothari S, Choi YJ, Dey A, Briles DE, Rhee DK, Carbis R.

Vaccine. 2015 Feb 4;33(6):783-8. doi: 10.1016/j.vaccine.2014.12.032.

PMID:
25545593
17.

Infection with conditionally virulent Streptococcus pneumoniae Δpab strains induces antibody to conserved protein antigens but does not protect against systemic infection with heterologous strains.

Chimalapati S, Cohen J, Camberlein E, Durmort C, Baxendale H, de Vogel C, van Belkum A, Brown JS.

Infect Immun. 2011 Dec;79(12):4965-76. doi: 10.1128/IAI.05923-11.

18.

Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.

Moore QC, Bosarge JR, Quin LR, McDaniel LS.

Vaccine. 2006 Jul 17;24(29-30):5755-61.

PMID:
16759765
19.

Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.

Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ.

Infect Immun. 2012 Mar;80(3):1166-80. doi: 10.1128/IAI.05511-11.

20.

Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface.

Ren B, Szalai AJ, Hollingshead SK, Briles DE.

Infect Immun. 2004 Jan;72(1):114-22.

Supplemental Content

Support Center